Methamphetamine Hydrochloride Tablet
NDC Package 0054-0389-25
Package Information
Methamphetamine Hydrochloride tablets is methamphetamine is contraindicated during or within 14 days following the administration of monoamine oxidase inhibitors; hypertensive crisis may result. This formulation utilizes a tablet delivery system. Marketed by Hikma Pharmaceuticals Usa Inc., this product is identified by NDC 0054-0389 and is authorized under FDA application ANDA203846.
Identification & Billing
- RxCUI: 977860 - methamphetamine HCl 5 MG Oral Tablet
- RxCUI: 977860 - methamphetamine hydrochloride 5 MG Oral Tablet
Clinical Specifications
- Amphetamine Anorectic - [EPC] (Established Pharmacologic Class)
- Amphetamines - [CS]
- Appetite Suppression - [PE] (Physiologic Effect)
- Central Nervous System Stimulant - [EPC] (Established Pharmacologic Class)
- Central Nervous System Stimulation - [PE] (Physiologic Effect)
- Increased Sympathetic Activity - [PE] (Physiologic Effect)
Regulatory & Marketing
Hierarchy Structure
- 0054 - Hikma Pharmaceuticals Usa Inc.
- 0054-0389 - Methamphetamine Hydrochloride
- 0054-0389-25 - 100 TABLET in 1 BOTTLE
- 0054-0389 - Methamphetamine Hydrochloride
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0054-0389-25 identifies a specific commercial package of 100 tablet in 1 bottle of Methamphetamine Hydrochloride, a human prescription drug labeled by Hikma Pharmaceuticals Usa Inc.. This tablet is formulated for oral use and contains methamphetamine hydrochloride as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Hikma Pharmaceuticals Usa Inc. on December 06, 2016. The current certification is valid through December 31, 2026.
How is this Hikma Pharmaceuticals Usa Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00054038925. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 100 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.